US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
FO

FOCL

$4.16
Sharia status
COMPLIANT
Per our secondary compliance provider · assessed 2026-08-25
HTR non-permissible income 0.36%

Methodology breakdown computing — it will appear here on its own.

🕌Open research, not a fatwa — verify with your own scholar.
Trade setup SEPARATE FROM SHARIAH
🟠 NOT YET
The main driver: lagging the market by 28.2%. More negatives than positives right now. The setup isn't ready — check...
44
of 100
Setup confidence — system conviction, not win probabilityD
Why this signal?
Structure1 of 5 timeframes bullish · 91.3% aligned
VWAPPrice below VWAP ($4.19)
VolumeRelative volume 2.1× the 20-day average
Momentum10-day rate of change -4.3%
Overall readNOT YET

EDAP TMS S.A. American Depositary Shares (FOCL) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-25). See the full ratio breakdown and business-activity screen below for the reasoning.

Market & analysts
Price target
$8.60
+106.7% · 5 analysts
Institutional own.
31.3%
of shares
Momentum (10d)
-4.3%
rate of change
SMC grade
D · 44
91.3% aligned
COMPLIANT
Sharia compliance
0.36%
Non-permissible income — HTR, from filings (2025-12-31)
D · 44
SMC grade — 91.3% timeframe alignment
-4.3%
Rate of change (10d)
$8.60
Price target (+106.7%) · 5 analysts
31.3%
Institutional ownership

🕌 In-house Compliance Research

Computing the full ratio and business-activity breakdown for FOCL — this runs off the critical path so the page paints first. It will appear here on its own.

6.345.214.082.941.812025-09-112026-03-122026-09-10

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
3.99
S2
4.05
S1
4.13
PIVOT
4.19
R1
4.27
R2
4.33
R3
4.41

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

7-day expected range
3.55667 4.88333
±15.72% from 4.22, made 2026-09-02 · resolves 2026-09-09
STRONG SELL
from 19 indicators
Not enough resolved predictions yet — 0 of 10 needed before we publish an accuracy figure. 21897 forecast(s) are currently open and will be scored automatically when their horizon expires.

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

Technical Summary

STRONG SELL
19 indicators
OscillatorsSTRONG SELL
1 buy · 4 neutral · 2 sell
Moving averagesSTRONG SELL
1 buy · 0 neutral · 11 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)33.00NEUTRAL
Stochastic %K (14)30.61NEUTRAL
CCI (20)-80.54NEUTRAL
Williams %R (14)-69.39NEUTRAL
MACD (12,26,9)0.02BUY
ROC (10)-5.67SELL
Momentum (10)-0.25SELL
EMA (10)4.25SELL
SMA (10)4.23SELL
EMA (20)4.46SELL
SMA (20)4.30SELL
EMA (30)4.64SELL
SMA (30)4.86SELL
EMA (50)4.78SELL
SMA (50)5.16SELL
EMA (100)4.66SELL
SMA (100)4.70SELL
EMA (200)4.10BUY
SMA (200)4.18SELL

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

About EDAP TMS S.A. American Depositary Shares

Healthcare · Medical Distribution

EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. It also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. In addition, the company manufactures and markets lithotripter for the treatment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters; and sells spare parts and disposables, such as electrodes. Further, it markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales channels, and third-party distributors and agents. The company serves academic, public, and private hospitals, as well as clinics. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop clinical workflows combining PSMA PET imaging and Focal One Robotic HIFU for prostate cancer. EDAP TMS S.A. was incorporated in 1979 and is headquartered in Vaulx-en-Velin, France.

investor.focalone.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Verdict

🟠 NOT YET

The main driver: lagging the market by 28.2%. More negatives than positives right now. The setup isn't ready — check back when the trend or RSI changes.

Scores: 1 bullish / 2 bearish

Grade verdict

Weak — low conviction, small size or skip

SMC — Top Down

TimeframeBiasBars
📅 Daily BEARISH 61
⏰ 4H BEARISH 25
🕐 1H BEARISH 98
⏱ 15-Min BULLISH 130
⏲ 5-Min BEARISH 234

Momentum & Volume

-0.30
MACD (no fresh cross)

Peer Movement

Peer movement computing — it will appear here on its own.

Insider Activity (90d)

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

NEUTRAL   report date 2026-09-01 · Asset managers net 934180 (-19048)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.

Tell us what's working, what's confusing, or what you want to see next — read by a real person, not a form that goes nowhere.